AIM: Activation of sphingosine kinase (SK) is a key response to many inflammatory processes. The present studies test the hypothesis that an orally available SK inhibitor, ABC294640, would be effective in rodent models of Crohn's disease. METHODS: Trinitrobenzene sulfonic acid (TNBS) was administered rectally to mice and rats. Rats were treated with ABC294640 orally alone or in combination with olsalazine and disease progression was monitored. RESULTS: For both rodent species, treatment with ABC294640 attenuated disease progression. Colon samples from the ABC294640-treated animals had improved histology and cytokine parameters when compared with vehicle-treated animals. The expression of SK was similarly increased in TNBS-treated animals and in human colon tissue specimens from inflammatory bowel disease patients relative to normal, control patients. CONCLUSIONS: Sphingosine kinase may be a critical mediator of colonic damage during intestinal inflammation, and pharmacologic inhibitors of this enzyme may prove useful in the treatment of Crohn's disease.
AIM: Activation of sphingosine kinase (SK) is a key response to many inflammatory processes. The present studies test the hypothesis that an orally available SK inhibitor, ABC294640, would be effective in rodent models of Crohn's disease. METHODS:Trinitrobenzene sulfonic acid (TNBS) was administered rectally to mice and rats. Rats were treated with ABC294640 orally alone or in combination with olsalazine and disease progression was monitored. RESULTS: For both rodent species, treatment with ABC294640 attenuated disease progression. Colon samples from the ABC294640-treated animals had improved histology and cytokine parameters when compared with vehicle-treated animals. The expression of SK was similarly increased in TNBS-treated animals and in human colon tissue specimens from inflammatory bowel diseasepatients relative to normal, control patients. CONCLUSIONS: Sphingosine kinase may be a critical mediator of colonic damage during intestinal inflammation, and pharmacologic inhibitors of this enzyme may prove useful in the treatment of Crohn's disease.
Authors: Kevin J French; John J Upson; Staci N Keller; Yan Zhuang; Jong K Yun; Charles D Smith Journal: J Pharmacol Exp Ther Date: 2006-04-21 Impact factor: 4.030
Authors: S Videla; J Vilaseca; C Medina; M Mourelle; F Guarner; A Salas; J-R Malagelada Journal: J Pharmacol Exp Ther Date: 2005-10-27 Impact factor: 4.030
Authors: Alison C MacKinnon; Avril Buckley; Edwin R Chilvers; Adriano G Rossi; Christopher Haslett; Tariq Sethi Journal: J Immunol Date: 2002-12-01 Impact factor: 5.422
Authors: Kevin J French; Yan Zhuang; Lynn W Maines; Peng Gao; Wenxue Wang; Vladimir Beljanski; John J Upson; Cecelia L Green; Staci N Keller; Charles D Smith Journal: J Pharmacol Exp Ther Date: 2010-01-08 Impact factor: 4.030
Authors: Elizabeth S Childress; Yugesh Kharel; Anne M Brown; David R Bevan; Kevin R Lynch; Webster L Santos Journal: J Med Chem Date: 2017-04-25 Impact factor: 7.446
Authors: Andrew J Kennedy; Thomas P Mathews; Yugesh Kharel; Saundra D Field; Morgan L Moyer; James E East; Joseph D Houck; Kevin R Lynch; Timothy L Macdonald Journal: J Med Chem Date: 2011-05-02 Impact factor: 7.446
Authors: Neeraj N Patwardhan; Emily A Morris; Yugesh Kharel; Mithun R Raje; Ming Gao; Jose L Tomsig; Kevin R Lynch; Webster L Santos Journal: J Med Chem Date: 2015-02-13 Impact factor: 7.446
Authors: Randy S Schrecengost; Cecelia L Green; Yan Zhuang; Staci N Keller; Ryan A Smith; Lynn W Maines; Charles D Smith Journal: J Pharmacol Exp Ther Date: 2018-02-06 Impact factor: 4.030
Authors: Yugesh Kharel; Mithun Raje; Ming Gao; Amanda M Gellett; Jose L Tomsig; Kevin R Lynch; Webster L Santos Journal: Biochem J Date: 2012-10-01 Impact factor: 3.857